N-(cyclohexylmethyl)-2-phenylacetamide | 1449232-29-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(cyclohexylmethyl)-2-phenylacetamide
• CAS: 1449232-29-4
• 化学式: C₁₅H₂₁NO
• 分子量: 231.338
• InChiKey: HRMJRVJYTAHAKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  环己甲胺 、 苯乙酸甲酯 在 potassium phosphate 、 2,2,2-三氟乙醇 作用下， 以 四氢呋喃 为溶剂， 反应 22.0h， 以64%的产率得到N-(cyclohexylmethyl)-2-phenylacetamide
  参考文献：
  名称：

  Catalytic amidation of unactivated ester derivatives mediated by trifluoroethanol

  摘要：

  已开发出一种实用的、催化的酰胺化协议，可使用廉价且易获得的试剂对未活化的酯进行酰胺化。

  DOI：

  10.1039/c5cc02895g

文献信息

• Nickel-Catalyzed Cross-Dehydrogenative Coupling of α-C(sp³)–H Bonds in <i>N</i>-Methylamides with C(sp³)–H Bonds in Cyclic Alkanes
  作者：Ze-Lin Li、Kang-Kang Sun、Chun Cai

  DOI：10.1021/acs.orglett.8b02736

  日期：2018.10.19

  A nickel-catalyzed cross-dehydrogenative coupling reaction of α-C(sp3)–H bonds in N-methylamides with C(sp3)–H bonds from cyclic alkanes has been developed, which offers a cheap transition-metal-catalyzed C–H activation method for amides without the requirement for any extraneous directing group. This new strategy is highly selective and tolerates a variety of functional groups. Mechanistic investigations

  已开发出镍催化的N-甲酰胺中的α-C（sp 3）-H键与环状烷烃的C（sp 3）-H键的交叉脱氢偶联反应，该反应可提供廉价的过渡金属催化的C -H活化酰胺的方法，不需要任何外来的导向基团。这种新策略具有高度的选择性，并且可以容忍各种功能组。还详细描述了对反应过程的机械研究。
• [EN] NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE SULFAMIDE PIPÉRAZINE À TITRE D'INHIBITEURS DE PROTÉINES TYROSINE KINASES ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：LEO PHARMA AS

  公开号：WO2012093169A1

  公开（公告）日：2012-07-12

  The invention relates to compounds of general Formula (I), Wherein R1, R2, R3, R4, R5, m, n are defined herein, and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof, for use - alone or in combination with one or more other pharmaceutically active compounds- in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disesase, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.

  该发明涉及一般式(I)的化合物，其中R1、R2、R3、R4、R5、m、n在此处定义，并且其药用可接受的盐、前药、水合物或溶剂化合物，用于单独或与一个或多个其他药用活性化合物结合在一起，在治疗中使用，作为JAK激酶和蛋白酪氨酸激酶抑制剂，用于预防、治疗或改善疾病及其并发症，包括例如牛皮癣、特应性皮炎、酒渣鼻、狼疮、多发性硬化症、类风湿关节炎、I型糖尿病、哮喘、癌症、自身免疫性甲状腺疾病、溃疡性结肠炎、克罗恩病、阿尔茨海默病、白血病、眼部疾病如糖尿病视网膜病变和黄斑变性以及其他自身免疫性疾病和免疫抑制希望的适应症，例如在器官移植中。
• Ruthenium-Catalyzed Redox-Neutral and Single-Step Amide Synthesis from Alcohol and Nitrile with Complete Atom Economy
  作者：Byungjoon Kang、Zhenqian Fu、Soon Hyeok Hong

  DOI：10.1021/ja404695t

  日期：2013.8.14

  A completely atom-economical and redox-neutral catalytic amide synthesis from an alcohol and a nitrite is realized. The amide C-N bond is efficiently formed between the nitrogen atom of nitrile and the alpha-carbon of alcohol, with the help of an N-heterocyclic carbene-based ruthenium catalyst, without a single by-product. A utility of the reaction was demonstrated by synthesizing C-13 or N-15 isotope-labeled amides without involvement of any separate reduction and oxidation step.
• NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF
  申请人：Leo Pharma A/S

  公开号：EP2661436A1

  公开（公告）日：2013-11-13
• US5541229A
  申请人：——

  公开号：US5541229A

  公开（公告）日：1996-07-30